AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02470806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO System
Description: Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
Study NCT02470806 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tNPWT System
Description: NPWT from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
Study NCT00866619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malaria Vaccine 257049
Description: administered intramuscularly into the left deltoid.
Study NCT01598337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: 10 mg daily as per instructions of investigators
Study NCT00866619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal C Conjugate Vaccine
Description: administered intramuscularly into the left deltoid.
Study NCT01598337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: 10 mg daily as per instructions of investigators
Study NCT00866619 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal C Conjugate Vaccine
Description: administered intramuscularly into the left deltoid.
Study NCT00866619 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cell-culture rabies vaccine
Description: administered intramuscularly into the left deltoid.
Study NCT00866619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TritanrixHepB/Hib
Description: administered intramuscularly into the left deltoid.
Study NCT01285310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg
Description: 30 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 30mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
Study NCT01285310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg
Description: 20 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
Study NCT01285310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Placebo tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in active treatment / active treatment extension phase. Participants who are nonresponders will advance early to 20 mg Apremilast BID at Week 16.
Study NCT01285310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in active treatment / active treatment extension phase. Participants who are nonresponders will advance early to 20 mg Apremilast BID at Week 16.
Study NCT00866619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin Oral Polio Vaccine (GSK)
Description: administered orally.
Study NCT05120336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation
Description: Non-invasive brain stimulation technique that is used to stimulate vagal afferent projections to the nucleus of the solitary tract. Invasive VNS has been approved for the treatment of treatment-resistant depression.
Study NCT05120336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham stimulation
Description: Sham procedure for active transcutaneous vagus nerve stimulation
Study NCT03284333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: other
Description: no arm
Study NCT02609750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured care & workplace intervention
Description: In addition to structured care a workplace intervention named Convergence Dialogue Meetings (CDM) are carried out. CDM is a three step structured dialogue and meeting model supporting the patient, health care professionals and employer to summarize concrete suggestions to support sustainable work ability and a return to work if sick listed.
Study NCT01694589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE-225
Description: LDE-225 capsules will be administered as a fixed dose of 800 mg daily for two weeks.
Study NCT04035681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy
Description: Problem-Solving Therapy is a brief psychosocial intervention for management of depressive symptoms. Participants will have six, one-hour sessions with an interventionist to learn a structured approach to problem-solving.
Study NCT04035681 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stroke-Related Health Education
Description: The stroke-related health education program will teach participants about various topics related to stroke. Participants will have six, one-hour sessions with an interventionist to learn about different topics related to stroke.
Study NCT03030872 — intervention group
Intervention type: DEVICE
Intervention: Investigational software
Description: The study evaluated retrospective de-identified cases that were processed after the imaging procedure had been completed (off-line) using a dedicated workstation.
Study NCT00536406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BE-ACTIV
Description: BE-ACTIV is 10-week behavioral treatment involving increasing pleasant events.
Study NCT00536406 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU includes usual treatment in nursing care facility.
Study NCT02103764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel
Description: Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
Study NCT02103764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone acetate
Description: Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
Study NCT00875212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium glycerophosphate
Description: use of a dentifrice containing CaGP (0.13%) and no fluoride
Study NCT00875212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: no active ingredient
Description: dentifrice without calcium glycerophosphate and no fluoride
Study NCT00875212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoride
Description: use of a dentifrice containing fluoride (1500ppm) only
Study NCT00875212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAGP + fluoride
Description: calcium glycerophosphate and fluoride dentifrice
Study NCT03491241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: hypocaloric diet therapy
Description: all patients will receive an hypocaloric diet, with low carboidrates (\<50%) overload.
Study NCT03491241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: hypocaloric diet therapy
Description: all patients will receive an hypocaloric diet, with low carboidrates (\<50%) overload.
Study NCT02934932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Comparison of brexpiprazole 2mg to placebo Comparison of brexpiprazole 4mg to placebo
Study NCT02934932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brexpiprazole
Description: Comparison of brexpiprazole 2mg to placebo Comparison of brexpiprazole 4mg to placebo
Study NCT02579915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FaceAnxiety
Description: Computerized treatment targeting mental habits and primary care linkage.
Study NCT02579915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Tracking
Description: Weekly self-assessment with validated questionnaires and primary care linkage
Study NCT02579915 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Tracking
Description: Weekly self-assessment with validated questionnaires and primary care linkage
Study NCT02176577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Product 0405
Description: Product 0405 will be administered topically, twice daily for 28 days.
Study NCT03180541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy
Description: Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
Study NCT03491241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: hypocaloric diet therapy
Description: all patients will receive an hypocaloric diet, with low carboidrates (\<50%) overload.
Study NCT03551860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TQL
Description: For the intervention of TQL peripheral nerve block the needle tip will be advanced by in-plane technique and local anaesthetic will be deposited between psoas major and quadratus lumborum muscles. 20 ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated.
Study NCT03551860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FIB
Description: The needle tip will be advanced by in-plane technique and local anaesthetic will be deposited deep to the fascia iliaca. 20ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated.
Study NCT02557646 — intervention group
Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2a
Description: Participants received pegylated interferon subcutaneous injection in accordance with current guidelines and SPCs.P
Study NCT02557646 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Participants received ribavirin 200 mg film-coated tablet in accordance with current guidelines and SPCs.
Study NCT02011737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naftopidil 75mg
Study NCT02379806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Study NCT02379806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00632411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Participants who smoke more than 20 cigarettes per day will use a 21-mg patch for 4 weeks, a 14-mg patch for the next 2 weeks, a 7-mg patch for the next 2 weeks, and then no patch.~Participants who smoke between 10 to 19 cigarettes per day will use a 14-mg patch for 4 weeks, a 7-mg patch for the next 4 weeks, and then no patch.~Participants who smoke between 5 to 9 cigarettes per day will use a 7-mg patch for 8 weeks and then no patch.~The proactive group will be given 8 weeks of patch treatment and the reactive group will be given 2 weeks of patch treatment.
Study NCT00632411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Quit Line Program
Description: Phone session 1 will focus on smoking reduction.~Phone session 2 will focus on preparing to quit and surviving the first days as a non-smoker. A quit date will be set in 7 to 10 days. Nicotine patches will be sent to participant with detailed instructions for patch use.~Phone session 3 will focus on the first days after the quit date.~Phone session 4 will focus on a review of progress and challenges of quitting. Plans to manage high-risk situations will be discussed.~Phone session 5 will focus on short-term relapse prevention.~Phone session 6 will focus on long-term relapse prevention.
Study NCT03971890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance therapy
Description: The experimental group will receive a dance treatment.This protocol will be administered at weekly sessions of 60 minutes with a period of 2 times / week with a total of 16 sessions, distributed over a 8-week period. They will be evaluated at baseline, after the end of the last treatment session.
Study NCT03971890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational group
Description: The control group will receive an educational intervention. They will be evaluated at baseline, after the end of the last treatment session.
Study NCT03153254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test upper limb robot assisted therapy device
Description: During 1 session of 1/2 hour.
Study NCT03153254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with new upper limb robot assisted therapy device
Description: During 2 to 5 sessions of 1/2 hour.
Study NCT01195415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01195415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01195415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study NCT04240925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIMV with sigh breaths
Description: Sigh breaths: Maximal Inspiratory pressure (IPAPmax) increased of at least 25% ( ≥ 125%) with a frequency of at least 1/200 breaths. The sigh breaths will be delivered as part of the standard NIMV protocol
Study NCT04240925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard NIMV
Description: Will be treated by standard NIMV with no sigh
Study NCT02155842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity endurance exercise
Study NCT02155842 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate continuous endurance exercise
Study NCT04208620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study NCT04208620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotadutide
Description: Cotadutide administered subcutaneously
Study NCT03930576 — intervention group
Intervention type: OTHER
Intervention: Receipt of termination services outside of legal setting
Description: This study uses variation in gestational age to examine the impact of receipt of legal termination services compared to denial and receipt outside legal settings and birth.
Study NCT02792933 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: air in epidural space
Description: The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be then withdrawn and the low resistance syringe filled with 3-5mL of air will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
Study NCT02792933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: saline in epidural space
Description: The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be withdrawn and the low resistance syringe filled with 3-5mL of saline solution will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
Study NCT00913003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)
Study NCT00913003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug
Study NCT01370174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Training Interventions
Description: Subjects will be assigned to one of four training groups. Training will occur three times weekly for twelve consecutive weeks. The IST group will receive waist-pulls by a motorized machine to produce stepping. Subjects in the HST group will perform muscle resistance exercises. Subjects in the combined IST and HST will receive both IST and HST interventions. Participants in the SFR group will perform flexibility and relaxation exercises.
Study NCT01370174 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical Training Interventions
Description: Subjects will be assigned to one of four training groups. Training will occur three times weekly for twelve consecutive weeks. The IST group will receive waist-pulls by a motorized machine to produce stepping. Subjects in the HST group will perform muscle resistance exercises. Subjects in the combined IST and HST will receive both IST and HST interventions. Participants in the SFR group will perform flexibility and relaxation exercises.
Study NCT01521455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0910
Description: 250/50, BID for 2 weeks
Study NCT01521455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Diskus
Description: 250/50, BID for 2 weeks
Study NCT02151253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil 50 - 250 mg pills Subjects took armodafinil once daily, before 8 am. Armodafinil was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
Study NCT02151253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Armodafinil
Description: Armodafinil 50 - 250 mg pills Subjects took armodafinil once daily, before 8 am. Armodafinil was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
Study NCT02151253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subject given placebo tablets to match Armodafinil pills. Subjects took placebo once daily, before 8 am. Placebo was initiated as 1 tablet and titrated to 3 tablets after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 5 tablets or reduced back to 1 tablet based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
Study NCT02151253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject given placebo tablets to match Armodafinil pills. Subjects took placebo once daily, before 8 am. Placebo was initiated as 1 tablet and titrated to 3 tablets after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 5 tablets or reduced back to 1 tablet based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.